New studies of two drugs, showing that each works better than the standard treatment for advanced kidney cancer, should lead to changes in patient care, researchers said on Friday. Toni Choueiri, associate professor of medicine at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, is quoted.
